Clinical Laserthermia Systems receives SEK 5.5 million order from ClearPoint Neuro
Lund, Sverige – Clinical Laserthermia Systems AB (publ) (CLS) today announced it has received an order for ClearPoint Prism™ Neuro Laser Therapy System products from ClearPoint Neuro, Inc (Nasdaq:CLPT). The deal has a total value of SEK 5.5 million. On September 23 2022, CLS received US FDA 510(k) clearance for its laser ablation system for use with MRI guidance in neurosurgery. Immediately followed by CLS’s global distributor initiating commercialization under the new brand name ClearPoint Prism™ Neuro Laser Therapy System. CLS has now received the first order for ClearPoint